Akkaraju joined the Menlo Park, Calif. office of New Leaf Venture Partners in January 2009, where he has worked on biopharmaceutical deals like Synageva BioPharma (GEVA) and Intercept Pharmaceuticals (ICPT). Sources say that he recently accepted a position with Sofinnova Ventures, although not all of his transition details have been finalized with New Leaf (where he remains on the company’s website).

A Sofinnova Ventures spokeswoman declined to comment, while Akkaraju did not respond to an email sent to his New Leaf account.

Before joining New Leaf, Akkaraju had been a co-founding partner of Panorama Capital — a venture capital firm formed when J.P. Morgan (JPM) chose to spin out JPMorgan Partners into a pair of independent firms (Panorama focuses on VC, while the buyout team became CCMP Capital). Akkaraju also had been with JPMorgan Partners, and also was a business and corporate development executive with Genentech Inc.

Sign up for Dan’s daily email newsletter on deals and deal-makers: GetTermSheet.com